How can digitalization in pharmaceutical manufacturing succeed in a GMP-compliant way and without data integrity risks?
We support life sciences companies through the digital transformation of regulated processes: from the digitalization roadmap to paperless manufacturing and the validated introduction of LIMS, eQMS, MES and ERP. Compliance is a design principle here, not an after-the-fact check. The real hurdle is rarely the technology, but the sequence: those who plan computer system validation, data integrity and change management too late build digital gaps that only surface during the GMP inspection audit.
- Pharma
- Biotech
- MedTech
- IVD
Overview
What requirements does the regulated environment place on digitalization projects?
Digitalization with compliance as a design principle · GAMP 5, EU GMP Annex 11, 21 CFR Part 11
Last updated: 2026-06-13
Digitalization in life sciences rarely fails because of the technology. It fails because paper-based GMP processes are transferred into electronic systems without considering the regulatory requirements from the outset. Four levers determine whether a project holds up:
- Every GMP-relevant system falls under EU GMP Guide Annex 11 and, where there is US market relevance, under 21 CFR Part 11: electronic records, audit trails, electronic signatures and access control must be evidenced across the entire lifecycle.
- The validation scope follows a risk-based approach in line with ISPE GAMP 5. Configured commercial off-the-shelf software requires a different effort than custom-developed software; the system category determines the depth of computer system validation.
- Data migration from legacy systems is the most common place where data integrity is lost. The completeness, legibility and traceability of the legacy data must remain demonstrable even after migration.
- Digitalization changes workflows and therefore the documented state under EU GMP Guide Chapter 4. Without change management and training, a gap arises between the described and the lived process, and that gap surfaces during inspection.
Services
How we support you
Digitalization Strategy & Roadmap
Prioritization of digitalization initiatives by benefit and GMP criticality, documented as a roadmap with milestones, dependencies and the investment required for each initiative.
Paperless Manufacturing
Design and introduction of electronic batch records, digital work instructions and electronic checklists, designed and validated in line with Annex 11 and 21 CFR Part 11 with a functioning audit trail.
System Selection & Implementation Support
Requirements catalog (User Requirements Specification) and selection of LIMS, eQMS, MES or ERP, with a validation strategy in line with GAMP 5 and go-live release against defined acceptance criteria.
Learn more →Data Migration & Data Integrity
Migration plan, validated data transfer and data integrity check in the target system in line with ALCOA principles, with documented evidence of the complete and unaltered legacy data.
Learn more →Digital Governance & Organization
Establishment of governance structures for digital systems: IT/OT delineation, data owners, role-based access concepts and integration into the existing QM system.
Learn more →Change Management & Training
Involvement of users, a training plan and handover into validated operation, documented through training records and a controlled transition from the paper-based to the electronic process.
Learn more →How we work together
What it comes down to
Digitalization in the regulated environment follows a sequencing logic, not a technology logic. Before a LIMS, eQMS, MES or ERP is configured, it must be established which system category applies under ISPE GAMP 5, because that category determines the depth of computer system validation. Only then is it worth building electronic batch records or migrating the legacy data. Those who reverse this sequence and use systems in production before the validation strategy is in place build in gaps against EU GMP Guide Annex 11 that can no longer be closed through rework, but only by rolling back commissioning.
The real bottleneck is usually data integrity at the transitions: during migration from legacy systems and during the switch from the paper-based to the electronic process. This is precisely where we engage early, because an audit trail that is never reviewed and a non-validated data transfer are the most common findings against Annex 11 and 21 CFR Part 11. The roadmap therefore moves the effort forward, into validation strategy and change management, to where corrections are inexpensive, rather than into the inspection audit, where they burden the entire project.
Our approach
Our approach
Step
Result
Site Assessment & Roadmap
Prioritized digitalization roadmap with GMP criticality, dependencies and the investment required for each initiative.
Requirements & System Selection
User Requirements Specification and a justified system decision with a defined conformity and validation path.
Validation Strategy
Risk-based validation plan in line with GAMP 5 with an assigned system category and test scope.
Data Migration
Validated data transfer with a documented data integrity check in the target system.
Validation & Go-Live
Accepted qualification, released system and a controlled transition into operation.
Handover & Change Management
Trained users, handed-over governance and operation integrated into the QM system.
Common pitfalls
Where projects commonly fail
Validation is planned as a downstream step.
If a GMP system is configured and used before the validation strategy in line with GAMP 5 is in place, the documented evidence for the qualified state is missing, and commissioning has to be rolled back.
The audit trail is functionally present but not reviewed.
Annex 11 and 21 CFR Part 11 require not only the recording of changes but also their regular risk-based review; an audit trail that is never examined is a common inspection finding.
Data migration is carried out without validation.
If legacy data is transferred without a migration plan and integrity check, it cannot later be demonstrated that the legacy data is present in the target system completely and unaltered, which violates data integrity under ALCOA.
The system category is classified incorrectly.
If configured commercial off-the-shelf software is treated like custom software, or vice versa, the result is either unnecessary validation effort or a validation gap that surfaces in an audit against GAMP 5.
Change management is treated as a soft accompanying measure.
If the switch from the paper-based to the electronic process is carried out without training and without updating the documentation under EU GMP Guide Chapter 4, the lived process diverges from the described one, and the project forfeits quality potential.
FAQ
Frequently asked questions
Sources
- EU GMP Guide Annex 11 (Computerised Systems): primary text
- 21 CFR Part 11 (Electronic Records; Electronic Signatures): FDA primary text
- ISPE GAMP 5 (A Risk-Based Approach to Compliant GxP Computerized Systems)
- EU GMP Guide Chapter 4 (Documentation)
- https://theentourage.de/expertise/digitalisierung/ (existing page content, revised)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Related insights
All insights →Regulations & standards considered
- EU GMP Guide Annex 11 (Computerised Systems)
- 21 CFR Part 11 (Electronic Records; Electronic Signatures)
- ISPE GAMP 5 (Risk-based approach for computerised systems)
- EU GMP Guide Chapter 4 (Documentation)
- Verordnung (EU) 2017/745 (MDR)
- Verordnung (EU) 2017/746 (IVDR)
- ISO 13485:2016 (QM system for medical devices)
Related topics
Computer System Validation →
CSV of digital systems in line with GAMP 5 and Annex 11
21 CFR Part 11 & Data Integrity →
Electronic records, audit trail and data integrity in line with ALCOA
Digital Governance →
Governance structures, data owners and access concepts for IT systems
ERP Integration →
ERP as the backbone of the digitalized value chain
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +49 89 4161170-0
info@theentourage.de
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences